Cystic Fibrosis: a Review of Pulmonary and Nutritional Therapies
Section snippets
Cystic fibrosis genetics
The CF gene was identified in 1989 and to date more than 1500 mutations have been described [1]. The CFTR mutations can be grouped into six classes [2]. Class 1 mutations affect the transcription of CFTR by formation of premature stop codons into the messenger RNA. In most cases the introduction of a premature stop codon results in a truncated protein that will undergo degradation through nonsense-mediated decay, resulting in total absence of CFTR protein. Class 2 mutations involve
Pathophysiology of cystic fibrosis pulmonary disease
The pulmonary manifestations are the main cause of morbidity and mortality in CF patients. CFTR is located on the apical surface of airway epithelial cells and serosal cells of the submucosal glands. A lack of CFTR activity leads to decreased chloride secretion as well as sodium hyperabsorption since one of the physiologic functions of CFTR is to inhibit the epithelial sodium channel [3]. This results in a decreased airway surface liquid volume, which leads to collapse of respiratory cilia,
Treatment of cystic fibrosis lung disease
Treatment of CF lung disease can be broadly divided into two categories based on their primary target within the cascade of CF pathophysiology (see Fig. 1) into symptomatic treatment that addresses downstream effects of the CFTR gene defect and those targeting the underlying abnormality. Symptomatic therapy includes anti-infective and anti-inflammatory therapies as well as agents that improve mucus clearance. Therapies that target the CFTR defect include airway surface fluid hydration, ion
Growth and nutrition
Malnutrition is a key feature of CF. Defective CFTR in the pancreatic epithelium results in ductal obstruction by proteinaceous secretions and acinar destruction. CF patients become pancreatic insufficient when more than 95% of total pancreatic exocrine function is lost [126]. These patients develop fat, protein, and carbohydrate malabsorption and are at risk for fat soluble vitamin deficiencies (ie, vitamins A, D, E, and K) as well as other mineral deficiencies.
Nutrition and lung function are
Cystic fibrosis–related diabetes
Cystic fibrosis–related diabetes (CFRD) can develop in CF patients as a consequence of the pancreatic pathology. The prevalence increases with age; the average age of onset is between 18 and 21 years [142]. It rarely develops in patients younger than age 10 [143]. Therefore, annual screening for CFRD with an oral glucose tolerance test starts at age 10.
The onset of CFRD is often insidious and the diagnosis is usually preceded by a decline in pulmonary function [144], [145]. Therefore, delaying
Summary
In summary, there is a significant interplay between the pulmonary manifestations and nutritional status of CF patients. The advances in CF clinical care in the past 2 decades are mainly attributed to anti-infective therapy as well as aggressive nutritional management. Currently, there are multiple therapeutic agents that are in clinical trial that target either the underlying CFTR defect or the downstream effects of CFTR. The broad spectrum of therapeutic agents being studied as well as the
References (148)
- et al.
Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
Cell
(1993) - et al.
Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized control trial
J Pediatr
(2002) - et al.
Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis
Lancet
(1985) - et al.
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
Lancet
(1991) - et al.
Mucolytics in cystic fibrosis
Paediatr Respir Rev
(2007) - et al.
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial
Lancet
(2005) - et al.
Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group
Chest
(1996) - et al.
Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis
Chest
(2005) - et al.
A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group
J Pediatr
(1995) - et al.
Glucocorticoids as an adjuvant treatment to intravenous antibiotics for cystic fibrosis pulmonary exacerbations: a UK Survey
J Cyst Fibros
(2007)
Oral corticosteroid therapy in cystic fibrosis patients hospitalized with for pulmonary exacerbation: a pilot study
Chest
The effects of non-steroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation
Eur J Pharmacol
Effects of ibuprofen on endotoxin-induced alveolitis: biphasic dose response and dissociation between inflammation and hypoxemia
Am J Med Sci
Effects of non-steroidal anti-inflammatory agents on human neutrophil functions in vitro and in vivo
Biochem Pharmacol
Use of high-dose ibuprofen in a pediatric cystic fibrosis center
J Cyst Fibros
High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial
J Pediatr
Anti-inflammatory effects of montelukast in mild cystic fibrosis
Ann Allergy Asthma Immunol
Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial
Lancet
Exploring the mechanisms of macrolides in cystic fibrosis
Respir Med
Aerosol alpha1-antitrypsin treatment for cystic fibrosis
Lancet
The CF salt controversy: in vivo observations and therapeutic approaches
Mol Cell
Inhalation of Moli1901 in patients with cystic fibrosis
Chest
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA
Science
Mechanisms of disease cystic fibrosis
N Engl J Med
Determinants of mortality from cystic fibrosis in Canada, 1970–1989
Am J Epidemiol
Clinical outcome after acquisition of Burkholderia cepacia in patients with cystic fibrosis
Ir J Med Sci
Current understanding of the inflammatory process in cystic fibrosis: onset and etiology
Pediatr Pulmonol
Early pulmonary inflammation in infants with cystic fibrosis
Am J Respir Crit Care Med
Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period
Arch Dis Child
German Board of the European Registry for Cystic Fibrosis (ERCF). Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis
Pediatr Pulmonol
Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients
J Clin Invest
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
Pediatr Pulmonol
Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis
Pediatr Pulmonol
Antibiotic therapy for chronic infection of Pseudomonas in the lung
Annu Rev Med
Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
Acta Paediatr Scand
Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa
Pediatr Pulmonol
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group
N Engl J Med
Nebulised anti-pseudomonal antibiotics for cystic fibrosis [review]
Cochrane Database Syst Rev
Cystic fibrosis pulmonary guidelines chronic medications for maintenance of lung health
Am J Respir Crit Care Med
Evaluation of inhaled colimycin in children with cystic fibrosis
Pediatr Pulmonol
Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
J Antimicrob Chemother
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
Eur Respir J
Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis
Pediatr Pulmonol
Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment
Pediatr Pulmonol
Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis
J Antimicrob Chemother
N-acetylcysteine reduces the risk of re-hospitalization among patients with chronic obstuctive pulmonary disease
Eur Respir J
Randomised controlled trial of N-Acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease
BMC Pulm Med
High dose oral N-acetylcysteine, a glutathione pro-drug, modulates inflammation in cystic fibrosis
Proc Natl Acad Sci U S A
Cited by (7)
Cystic fibrosis
2023, Encyclopedia of Human Nutrition: Volume 1-4, Fourth EditionCystic Fibrosis
2012, Encyclopedia of Human NutritionApplications of PET/CT in Pediatric Patients with Fever of Unknown Origin
2008, PET ClinicsCitation Excerpt :It has been reported that in patients with biopsy-proven intravascular lymphomatosis who presented with FUO, diagnostic CT scan was negative but there were multiple sites of abnormal FDG activity on PET images.143 Cystic fibrosis, another rare chronic multisystem disorder, is characterized by recurrent endobronchial infections, progressive obstructive pulmonary disease, and pancreatic insufficiency with intestinal malabsorption.144,145 Chen and Schuster146 in their study with 20 patients with cystic fibrosis concluded that the amount of FDG uptake by the lungs is correlated with the inflammatory burden in patients with cystic fibrosis.
Protein is an important but undervalued macronutrient in the nutritional care of patients with cystic fibrosis
2014, Current Opinion in Clinical Nutrition and Metabolic CareMalnutrition in children with cystic fibrosis
2013, PediatriyaImproving nutritional status of children with cystic fibrosis at Red Cross War Memorial Children's Hospital
2011, Journal of Paediatrics and Child Health